Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2004 | Review

Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives

Authors: Hui-Chuan Sun, Zhao-You Tang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2004

Abstract

Hepatocellular carcinoma (HCC) is a typical hypervascular tumor. Many angiogenic factors have been studied in HCC, and several anti-angiogenic therapies have been tested in animal models and patients. This paper summarizes the latest findings, especially regarding the clinical significance of endothelial cell markers and angiogenic factors in HCC, and experimental and clinical anti-angiogenesis therapies. Further developments in this area, such as endothelial cell-oriented research and better experimental and clinical designs in the evaluation of anti-angiogenic therapies are discussed.

Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y (1994) A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54:3407–3412PubMed

An FQ, Matsuda M, Fujii H, Matsumoto Y (2000) Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 126:153–160PubMed

Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM (1996) Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97:2792–2802PubMed

Ball HJ, McParland B, Driussi C, Hunt NH (2002) Isolating vessels from the mouse brain for gene expression analysis using laser capture microdissection. Brain Res Brain Res Protoc 9:206–213CrossRefPubMed

Baur M, Walter R, Gebauer A, Tscholakoff D, Lochs H, Muhlbacher F, Turetschek K, Binder R, Hudec M, Gangl A, Ferenci P, Dittrich C (2003) Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study. Int J Oncol 23:811–819PubMed

Bernardini G, Ribatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A, Capogrossi MC, Napolitano M (2003) Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273:83–101CrossRefPubMed

Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, Aguggini S, Brunelli A, Betri E, Generali D, Scaratti L, Bertoli G, Alquati P, Dogliotti L (2002) Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 8:1816–1821PubMed

Camma C, Giunta M, Andreone P, Craxi A (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34:593–602CrossRefPubMed

Catalano A, Romano M, Martinotti S, Procopio A (2002) Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene 21:2896–2900CrossRefPubMed

Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10:355–362CrossRefPubMed

Cui S, Hano H, Sakata A, Harada T, Liu T, Takai S, Ushigome S (1996) Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol Int 46:751–756PubMed

De Bouard S, Guillamo JS, Christov C, Lefevre N, Brugieres P, Gola E, Devanz P, Indraccolo S, Peschanski M (2003) Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther 14:883–895CrossRefPubMed

Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS (1998) Fumagillin analog in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 16:1444–1449PubMed

Dhar DK, Ono T, Yamanoi A, Soda Y, Yamaguchi E, Rahman MA, Kohno H, Nagasue N (2002) Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 95:2188–2195CrossRefPubMed

Dhillon AP, Colombari R, Savage K, Scheuer PJ (1992) An immunohistochemical study of the blood vessels within primary hepatocellular tumours. Liver 12:311–318PubMed

Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Markidou S, Panagiotakos D, Chrysohoou C, Bazinis A, Paraskevas E (2002) The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245–1250

Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393PubMed

El Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue N (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554–1562

El Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7:1299–1305PubMed

Farinelle S, Malonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, Darro F, Fontaine J, Atassi G, Kiss R (2000) Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol Methods 43:15–24CrossRefPubMed

Favre CJ, Mancuso M, Maas K, McLean JW, Baluk P, McDonald DM (2003) Expression of genes involved in vascular development and angiogenesis in endothelial cells freshly isolated from adult lungs. Am J Physiol Heart Circ Physiol 285:H1917–1938PubMed

Finger AN, Bisoffi M, Wetterwald A, Gautschi E, Hohenfeld U, Klima I, Stadler BM, Mazzucchelli L, Thalmann GN, Cecchini MG (2002) Scavenger receptor block as strategy for the identification of bone marrow homing phages by panning in vivo random peptide phage displayed libraries. J Immunol Methods 264:173–186CrossRefPubMed

Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144:1574–1584CrossRefPubMed

Folkman J, Hahnfeldt P, Hlatky L (2000) Cancer: looking outside the genome. Nat Rev Mol Cell Biol 1:76–79CrossRefPubMed

Frachon S, Gouysse G, Dumortier J, Couvelard A, Nejjari M, Mion F, Berger F, Paliard P, Boillot O, Scoazec JY (2001) Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 34:850–857CrossRefPubMed

Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O’Reilly MS (2003) Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg 237:530–535CrossRefPubMed

Hattori M, Fukuda Y, Imoto M, Koyama Y, Nakano I, Urano F (1991) Histochemical properties of vascular and sinusoidal endothelial cells in liver diseases. Gastroenterol Jpn 26:336–343PubMed

Hazzard TM, Rohan RM, Molskness TA, Fanton JW, D’Amato RJ, Stouffer RL (2002) Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function. Endocrine 17:199–206CrossRefPubMed

Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK (2002) Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20:4440–4447CrossRefPubMed

Higgins RD, Yan Y, Schrier BK (2002) Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 74:553–559CrossRef

Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, Cheng JS, Huang JS, Ger LP, Huang SM, Yen MY, Yang YF (1997) Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 17:2803–2809PubMed

Huang J, Soffer SZ, Kim ES, Yokoi A, Moore JT, McCrudden KW, Manley C, Middlesworth W, O’Toole K, Stolar C, Yamashiro DJ, Kandel JJ (2002) p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease. J Pediatr Surg 37:523–527CrossRefPubMed

Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, Kumada H (1998) Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 82:827–835CrossRefPubMed

Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228–232PubMed

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555–557PubMed

Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570–576PubMed

Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, Wang J, Li JS, Zhai ZM, Xue Q (2003) Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 129:327–334CrossRefPubMed

Jin-no K, Tanimizu M, Hyodo I, Kurimoto F, Yamashita T (1997) Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol 32:119–121PubMed

Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Endo H, Yamashita T, Okada Y (1998) Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33:376–382CrossRefPubMed

Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J (1999) Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 103:1145–1149PubMed

Ker CG, Chen HY, Juan CC, Lo HW, Shen YY, Chen JS, Lee KT, Sheen PC (1999) Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology 46:646–650PubMed

Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739CrossRefPubMed

Kim YB, Park YN, Park C (2001) Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38:160–166PubMed

Kim YI, Song KE, Ryeon HK, Hwang YJ, Yun YK, Lee JW, Chun BY (2002) Enhanced inflammatory cytokine production at ischemia/reperfusion in human liver resection. Hepatogastroenterology 49:1077–1082PubMed

Kin M, Sata M, Ueno T, Torimura T, Inuzuka S, Tsuji R, Sujaku K, Sakamoto M, Sugawara H, Tamaki S, Tanikawa K (1997) Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 27:677–687CrossRefPubMed

Kin M, Torimura T, Ueno T, Nakamura T, Ogata R, Sakamoto M, Tamaki S, Sata M (2000) Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 16:375–382PubMed

Klagsbrun M, Sasse J, Sullivan R, Smith JA (1986) Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci USA 83:2448–2452PubMed

Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y (2002) Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 65:200–206CrossRefPubMed

Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447PubMed

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H (2001) Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963–967PubMed

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H (2002) Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418–422CrossRefPubMed

Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ (2003) Tissue-specific Microvascular Endothelial Cell Lines from H-2 K(b)-tsA58 Mice for Studies of Angiogenesis and Metastasis. Cancer Res 63:2971–2976

Lee SW, Lee YM, Bae SK, Murakami S, Yun Y, Kim KW (2000) Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun 268:456–461PubMed

Li XM, Tang ZY, and Chen FG (1998a) Mutant Flk-1 transfection in HCC inhibited angiogenesis, growth and metastasis in nude mice model. Chin J Biol Treat Cancer 5:160–162

Li XM, Tang ZY, Zhou G, Liu YK, Ye SL (1998b) Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17:13–17PubMed

Li XM, Tang ZY, Qin LX, Zhou J, Sun HC (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 18:511–517PubMed

Lisa MC and Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefPubMed

Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodes J, Bruix J (2000) Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31:54–58PubMed

Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU (2001) Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198–1203PubMed

Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, Mulliken JB, Folkman J (2002) Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 109:E37PubMed

Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23:455–464PubMed

Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y, Miyazaki M (2003) Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37:1105–1113CrossRefPubMed

Moller PH, Ivarsson K, Roos G, Radnell M, Persson B, Tranberg KG, Stenram U (1997) Angiogenesis inhibitor TNP-470 augments the effect of repeated arterial ischemia on growth but does not affect take in a rat liver tumor model. Anticancer Res 17:2401–2406PubMed

Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS (2003) Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16:552–557PubMed

Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM (1999) Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154:1503–1512PubMed

Morales C, Zurita M, Vaquero J (2002) Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor. J Neurooncol 58:131–136CrossRefPubMed

Moriguchi M, Nakajima T, Kimura H, Watanabe T, Takashima H, Mitsumoto Y, Katagishi T, Okanoue T, Kagawa K (2002) The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 102:445–452CrossRefPubMed

Morinaga S, Imada T, Shimizu A, Akaike M, Sugimasa Y, Takemiya S, Takanashi Y (2001) Angiogenesis in hepatocellular carcinoma as evaluated by alpha smooth muscle actin immunohistochemistry. Hepatogastroenterology 48:224–228PubMed

Moscatelli DA, Rifkin DB, Jaffe EA (1985) Production of latent collagenase by human umbilical vein endothelial cells in response to angiogenic preparations. Exp Cell Res 156:379–390PubMed

Motoo Y, Sawabu N, Yamaguchi Y, Terada T, Nakanuma Y (1993) Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor. Oncology 50:270–274PubMed

Mugitani T, Taniguchi H, Takada A, Yamaguchi A, Masuyama M, Hoshima M, Takahashi T (1998) TNP-470 inhibits collateralization to complement the anti-tumour effect of hepatic artery ligation. Br J Cancer 77:638–642PubMed

Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S (2001) Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33:346–356CrossRefPubMed

Musso O, Rehn M, Theret N, Turlin B, Bioulac-Sage P, Lotrian D, Campion JP, Pihlajaniemi T, Clement B (2001a) Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res 61:45–49PubMed

Musso O, Theret N, Heljasvaara R, Rehn M, Turlin B, Campion JP, Pihlajaniemi T, Clement B (2001b) Tumor hepatocytes and basement membrane-Producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatology 33:868–876PubMed

Nakamura S, Muro H, Suzuki S, Sakaguchi T, Konno H, Baba S, Syed AS (1997) Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. Hepatology 26:407–415PubMed

Nakayama K, Kanzaki A, Takebayashi Y, Toi M, Bando H, Nabei T, Miyazaki K, Fukumoto M (2001) Different features of angiogenesis between ovarian and breast carcinoma. Cancer Lett 170:161–167CrossRefPubMed

Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838–845PubMed

Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M (1996) Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 24:198–205PubMed

Ohno S, Nishi T, Kojima Y, Haraoka J, Ito H, Mizuguchi J (2002) Combined stimulation with interferon alpha and retinoic acid synergistically inhibits proliferation of the glioblastoma cell line GB12. Neurol Res 24:697–704PubMed

Park YN, Kim YB, Yang KM, Park C (2000) Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061–1065PubMed

Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364–366PubMed

Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM (2003) Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21:421–427CrossRefPubMed

Piccaluga PP, Visani G, Isidori A, Malagola M, Ascani S, Pileri SA (2003) Microdose alpha-interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report. Leukemia 17:986–987CrossRefPubMed

Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500–507CrossRefPubMed

Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J (2001a) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304CrossRefPubMed

Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J (2001b) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235CrossRefPubMed

Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775–1785CrossRefPubMed

Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST (2003) Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 63:3121–3126

Porrata LF, Inwards DJ, Lacy MQ, Markovic SN (2001) Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation. Bone Marrow Transplant 28:673–680CrossRefPubMed

Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677-684CrossRefPubMed

Rak J, Kerbel RS (2001) Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 333:267–283PubMed

Rak JW, St Croix BD, Kerbel RS (1995) Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6:3-18

Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B (1999) Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45:766–774PubMed

Roncalli M, Roz E, Coggi G, Di Rocco MG, Bossi P, Minola E, Gambacorta M, Borzio M (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30:1174–1178PubMed

Ruck P, Xiao JC, Kaiserling E (1995) Immunoreactivity of sinusoids in hepatocellular carcinoma. An immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34. Arch Pathol Lab Med 119:173–178PubMed

Sakamoto M, Ino Y, Fujii T, Hirohashi S (1993) Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma. Jpn J Clin Oncol 23:98–104PubMed

Sedlakova O, Sedlak J, Hunakova L, Jakubikova J, Duraj J, Sulikova M, Chovancova J, Chorvath B (1999) Angiogenesis inhibitor TNP-470: cytotoxic effects on human neoplastic cell lines. Neoplasma 46:283–289PubMed

Shin EC, Choi YH, Kim JS, Kim SJ, Park JH (2002) Expression patterns of cytokines and chemokines genes in human hepatoma cells. Yonsei Med J 43:657–664PubMed

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M (2003) Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299–306PubMed

Shouval D (1998) Octreotide in hepatocellular carcinoma. Gut 42:316–317PubMed

Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB, Killion JJ, Fidler IJ (2003) Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 9:1858–1867PubMed

Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ (1999) Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17:2541–2545PubMed

St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes expressed in human tumor endothelium. Science 289:1197–1202PubMed

Stern JW, Fang J, Shusterman S, Pierson G, Barr R, Pawel B, Diller L, Grupp SA (2001) Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res 7:1026–1032PubMed

Su X, Sorenson CM, Sheibani N (2003) Isolation and characterization of murine retinal endothelial cells. Mol Vis 9:171–178PubMed

Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, Ma ZC (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239–243CrossRefPubMed

Sun HC, Zhang M, Tang ZY, Li XM, Wang L, Gao DM, Xue Q, Chen J (1999a) endostatin inhibited the growth of human HCC subcutaneously implanted in nude mice. Chin J Exp Surg 16:495–497

Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC (1999b) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 125:419–426CrossRefPubMed

Sun HC, Zhang M, Tang ZY, Wang L, Li XM, Gao DM, Xue Q, Chen J (2000) endostatin inhibited growth and metastasis of human HCC transplanted in nude mice after resection. Chin J Oncol 22:80–81

Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T, Aoyagi Y (2003) Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver 23:143–147PubMed

Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H (2001) Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7:3410–3415PubMed

Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Higashida T, Koyama H, Suganuma Y, Miyata K, Takeuchi K (1995) Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br J Cancer 72:650–653PubMed

Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Koyama H, Hoshima M, Takahashi T (1996) Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 83:1444–1447PubMed

Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341–345PubMed

Tanigawa N, Lu C, Mitsui T, Miura S (1997a) Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26:1216–1223PubMed

Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA (1995) Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7:237–243PubMed

Terada T, Nakanuma Y (1995) Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas. Histopathology 27:333–339PubMed

Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81:814–821PubMed

Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K (1998) Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29:986–991PubMed

Tsukamoto A, Kaneko Y, Yoshida T, Ichinose M, Kimura S (1999) Regulation of angiogenesis in human hepatomas: possible involvement of p53-inducible inhibitor of vascular endothelial cell proliferation. Cancer Lett 141:79–84PubMed

von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S (2001) Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48:87-96PubMed

von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95:437–448PubMed

Wadzinski MG, Folkman J, Sasse J, Devey K, Ingber D, Klagsbrun M (1987) Heparin-binding angiogenesis factors: detection by immunological methods. Clin Physiol Biochem 5:200–209PubMed

Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL (2000) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43–48PubMed

Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY (2003) Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 7:587–594CrossRefPubMed

Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O’Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M (2003) Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 120:452–456CrossRefPubMed

Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268–275CrossRefPubMed

Xia JL, Yang BH, Tang ZY, Sun FX, Xue Q, Gao DM (1997) Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 123:383–387CrossRefPubMed

Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68–77

Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ, Kojiro M (2000) Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7:725–729PubMed

Yamamoto A, Dhar DK, El Assal ON, Igarashi M, Tabara H, Nagasue N (1998) Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol 29:290–299CrossRefPubMed

Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, Kojiro M (1999) Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29:1708–1717PubMed

Yeh JR, Mohan R, Crews CM (2000) The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 97:12782–12787PubMed

Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, Nakatani T, Fukui H (1998) Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28:1489–1496

Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H (1999) KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30:1179–1186PubMed

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Huber J, Nakatani T, Tsujinoue H, Yanase K, Imazu H, Fukui H (2002) Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35:834–842CrossRefPubMed

Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL (2001) Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34:139–145CrossRefPubMed

Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36:687–691CrossRefPubMed

Yuen MF, Ooi CG, Hui CK, Wong WM, Wong BC, Chan AO, Lai CL (2003) A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 97:2776–2782CrossRefPubMed

Zalatnai A, Timar F (2002) In vitro antiangiogenic effect of sandostatin (octreotide) on the proliferation of the placental vessels. Anticancer Res 22:4225-4227PubMed

Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL (2000) Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57–61PubMed

Title: Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives
Authors: Hui-Chuan Sun
Zhao-You Tang
Publication date: 01-06-2004
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-003-0530-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2004

Fatigue in patients with adjuvant radiation therapy for breast cancer: long-term follow-up

High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literature

Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11

Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma

Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma

Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page